Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Quibim and Merck Forge Partnership to Pioneer Advanced Imaging-Based Diagnostics for Precision Medicine in Oncology

NextEdge Admin

31 Jan 2024

2 min 51 sec

Quibim, with offices at the Science Park in Cambridge, has joined forces with Merck KGaA to pioneer the next generation of precision medicine technology, focusing on various cancers. Globally, Quibim specializes in converting imaging data into actionable predictions for cancer progression and treatment response, while Merck operates in Healthcare, Life Science, and Electronics. The collaboration aims to leverage biomarkers and radiomics to foresee cancer patients’ responses to immunotherapy and predict outcomes. Quibim’s expertise in AI will contribute to developing predictive models, enhancing patient stratification, and contextualizing benefits of novel therapies at a patient, dose, or treatment level. Merck plans to integrate these models into its data-driven decision-making for drug development.

Efficient clinical development for cancer medicine is crucial due to the rising number of cancer patients. Quibim and Merck are committed to researching technological solutions that reduce costs and timelines for pharmaceutical development. The partnership also focuses on addressing the anticipated increase in global cancer cases, estimated at 30 million new cases annually by 2040. Quibim’s CEO, Angel Alberich-Bayarri, views the collaboration as a game-changer in oncology, aiming to usher in a new era of precision medicine with data-driven insights for more efficient and tailored treatments.

Quibim recently achieved a hat-trick of successes with its AI-based products. QP-Prostate, with cancer detection capability, received CE and UKCA marks, offering a solution for processing prostate cancer imagery efficiently. QP-Brain, an AI-based neurological disease software, gained authorization for use in the US, EU, and UK, providing quantitative assessments to detect early-stage changes in the brain. This addresses the growing demand for advanced tools in neurological disease detection. The product is compliant with data protection regulations, ensuring secure processing and analysis of patient data in healthcare institutions.